Phase II clinical study for anlotinib combined with stereotactic radiotherapy for brain metastasis of non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019580

Enrollment

Unknown

Registered

2018-11-18

Start date

2018-11-13

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none small cell lung cancer

Interventions

Case series:Stereotactic radiotherapy combined with anlotinb

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. brain metastases of non-small cell lung cancer after second line treatment

Exclusion criteria

Exclusion criteria: 1. central lung cancer with hemorrhage or other parts of the body bleeding; 2. Contraindication of other drugs; 3. Untreated Patients with clear mutations in EGFR, ALK, ROS1, T790M.

Design outcomes

Primary

Measure	Time frame
local control;	—

Countries

China

Contacts

Public ContactZhuang Hongqing

Department of Radiation Oncology, Peking University Third Hospital

hongqingzhuang@163.com+86 13051776232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026